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Abstract
Background & Aims:	This	 study	aimed	 to	assess	 the	 real-	life	clinical	and	virological	
outcomes	of	HCV	waitlisted	patients	for	liver	transplantation	(LT)	who	received	sofos-
buvir/ribavirin	(SOF/R)	within	the	Italian	compassionate	use	program.
Methods:	Clinical	and	virological	data	were	collected	in	224	patients	with	decompen-
sated	cirrhosis	and/or	hepatocellular	carcinoma	(HCC)	receiving	daily	SOF/R	until	LT	
or	up	a	maximum	of	48	weeks.
Results:	 Of	 100	 transplanted	 patients,	 51	 were	 HCV-	RNA	 negative	 for	 >4	weeks	
	before	LT	(SVR12:	88%)	and	49	negative	for	<4	weeks	or	still	viraemic	at	transplant:	
34	patients	continued	treatment	after	LT	(bridging	therapy)	(SVR12:	88%),	while	15	
stopped	treatment	(SVR12:	53%).	98	patients	completed	SOF/R	without	LT	(SVR12:	
73%).	 In	patients	with	advanced	decompensated	cirrhosis	 (basal	MELD	≥15	and/or	
C-	P	≥B8),	a	marked	improvement	of	the	scores	occurred	in	about	50%	of	cases	and	
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1  | INTRODUCTION
The	 treatment	 paradigm	 for	 patients	 with	 decompensated	 hepatitis	
C	(HCV)	cirrhosis	has	changed	dramatically	after	the	introduction	of	the	
direct-	acting	antivirals	 (DAA)	 leading	to	sustained	virological	 response	
(SVR)	 rates	as	high	as	75%-	90%	 in	patients	with	Child-	Pugh	B	and	C	
	cirrhosis.1-4	Moreover,	DAAs	have	a	remarkably	good	safety	profile	even	
if	a	risk	of	inducing	hepatic	decompensation	with	NS3	protease	inhibi-
tors	has	been	reported.5	As	a	result,	HCV-	infection	can	be	now	effec-
tively	and	safely	cured	in	patients	waiting	for	liver	transplantation	(LT).
A	major	goal	of	treating	HCV	infection	in	these	patients	is	to	avoid	
its	recurrence	after	LT.	Prevention	of	allograft	reinfection	may	provide	
a	relevant	advantage	in	the	post-	transplant	management,	especially	in	
areas	where	the	donor	age	greatly	increased	above	60	years	in	the	last	
decade,	leading	to	a	more	severe	HCV	recurrence.6	Treatment	should	
be	 initiated	 if	 patients	 have	 sufficient	 time	 to	 achieve	undetectable	
HCV-	RNA	before	LT,	but	the	timing	to	transplantation	is	often	unpre-
dictable.	Thus,	 a	 reasonable	 alternative	 strategy	 is	 to	 differ	 therapy	
after	LT,	as	the	reported	SVR	rates	in	transplant	recipients	are	higher	
than	those	with	decompensated	cirrhosis	with	an	excellent	drug	safety	
profile.7
Treatment	with	DAAs	before	LT	is	also	associated	to	an	improve-
ment	 of	 liver	 function	 in	 many	 patients,	 thus	 reducing	 waiting-	list	
mortality	 and	 even	 leading	 to	 inactivation	 and	withdrawal	 from	 the	
transplant	 list	 in	 some	 cases.8,9	However,	 if	 liver	 function	 improves	
during	treatment	but	does	not	eliminate	the	need	for	LT,	these	patients	
are	at	disadvantage	for	graft	allocation	when	the	system	is	based	only	
on	 the	MELD	scoring	 system.	Moreover,	many	patients	with	 severe	
liver	diseases	have	no	reduction	of	Child-	Pugh	and	MELD	scores	or	
continue	to	show	disease	progression	following	successful	treatment,	
indicating	the	existence	of	a	point	of	no	return	for	recovery.1-4
Unfortunately,	 clinical	 evidences	 in	 the	pretransplant	 setting	are	
quite	limited.	In	the	pivotal	study	by	Curry	et	al10	including	waitlisted	
patients	 with	 Child-	Pugh	 score	 ≤B7	 and	 hepatocellular	 carcinoma	
(HCC),	the	combination	of	sofosbuvir	plus	ribavirin	(SOF/R)	prevented	
HCV	 recurrence	 in	 96%	 of	 patients	with	 undetectable	 viraemia	 for	
at	least	4	weeks	before	LT,	but	only	in	36%	with	undetectable	virae-
mia	for	less	than	4	weeks.	De-	listing	was	reported	in	18%	of	patients	
waiting	 for	 LT	 after	 treatment	with	 SOF-	based	 regimes	 in	 a	 French	
multicentre	 cohort.9	 More	 recently,	 a	 retrospective	 analysis	 of	 103	
patients	 listed	 in	 several	 European	 centres	 for	 decompensated	 cir-
rhosis	without	HCC	showed	that	treatment	with	SOF-	based	regimens	
favoured,	in	a	time-	frame	of	60	weeks,	the	inactivation	from	the	list	of	
about	one-	third	of	cases	and	delisting	of	about	20%	of	cases.8	Thus,	
additional	data	are	needed	to	clarify	the	open	issues	regarding	DAAs	
treatment	in	patients	waiting	for	LT.
Here	we	report	the	real-	life	virological	and	clinical	outcomes	of	a	
large	cohort	of	224	patients	waitlisted	for	LT	affected	by	HCV-	related	
cirrhosis	with	or	without	HCC,	who	received	SOF/R	within	the	frame	
of	a	national	compassionate	program.
2  | PATIENTS AND METHODS
2.1 | Patients and design of the study
Patients	waiting	for	LT	in	Italian	transplant	centres	and	participating	from	
June	2014	to	December	2014	to	the	Italian	compassionate	program	for	
almost	20%	of	decompensated	patients	without	HCC	reached	a	condition	suitable	for	
inactivation	and	delisting.
Conclusions:	These	real-	life	data	indicate	that	in	waitlisted	patients:	(i)	bridging	antivi-
ral	therapy	can	be	an	option	for	patients	still	viraemic	or	negative	<4	weeks	at	LT;	and	
(ii)	clinical	improvement	to	a	condition	suitable	for	delisting	can	occur	even	in	patients	
with	advanced	decompensated	cirrhosis.
K E Y W O R D S
bridging	therapy,	decompensated	cirrhosis,	delisting,	direct-acting	antivirals,	hepatitis	C,	liver	
transplantation
Key points
•	 Viral	eradication	is	associated	to	an	improvement	of	liver	
function	 in	 about	 half	 of	 patients	 awaiting	 liver	
transplantation.
•	 A	 condition	 of	 inactivation	 and	 then	 de-listing	 can	 be	
reached	in	almost	20%	of	non-HCC	patients	even	in	some	
of	those	with	a	severely	compromised	liver	function.
•	 A	decrease	of	MELD	score	after	4	weeks	of	therapy	can	
help	 to	 identify	 patients	 with	 the	 highest	 chances	 to	
achieve	inactivation.
•	 Pretransplant	sofosbuvir	plus	ribavirin	antiviral	treatment	
can	prevent	graft	reinfection	in	almost	90%	of	the	recipi-
ents	provided	that	bridging	therapy	is	performed	in	those	
patients	still	viraemic	or	negative	for	less	than	4	weeks	at	
transplantation.
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the	use	of	SOF	(ITACOPS)	were	included	in	this	prospective,	observa-
tional	cohort	study.	ITACOPS	was	promoted	by	the	Italian	Association	
for	the	Study	of	the	Liver	(AISF)	and	the	Italian	Society	of	Infectious	and	
Tropical	Diseases	(SIMIT)	and	endorsed	by	the	Italian	Medicines	Agency	
(AIFA).	SOF	was	kindly	provided	by	Gilead	Sciences	at	no	cost	for	Italian	
National	Health	System.
Inclusion	criteria	were:	age	>18	years,	registration	in	a	LT	waiting	
list,	decompensated	cirrhosis	(Child-	Pugh	≥B7),	and	HCC	within	Milan	
criteria	independently	of	the	severity	of	the	underlying	liver	disease.	
Exclusion	criteria	were:	MELD	score	≥25,	creatinine	clearance	≤30	mL/
min,	 according	 with	 the	 SOF	 Summary	 of	 Product	 Characteristics,	
pregnant/nursing	women,	 and	 history	 of	 significant	 drug	 allergy	 to	
	nucleoside/nucleotide	analogues.
The	 study	 conforms	 to	 the	 ethical	 guidelines	 of	 the	 1975	
Declaration	 of	 Helsinki	 and	 all	 patients	 gave	 their	 written	 consent	
to	 participate	 in	 the	 study.	 The	 study	was	 approved	 by	 the	 Ethical	
Committee	of	the	S.	Orsola-	Malpighi	University	Hospital	of	Bologna	
and	by	Ethical	Committees	of	all	participating	centres.
2.2 | Treatments
Patients	 were	 enrolled	 to	 receive	 daily	 SOF	 (400	mg	 daily)	 plus	
weight-	based	R	(1000-	1200	mg	daily)	until	LT	or	for	a	maximum	of	24	
weeks	(genotype	2)	or	48	weeks	(all	other	genotypes).	 Investigators	
were	allowed	to	add	a	second	DAA	if	obtained	for	the	compassionate	
use.	All	patients	were	also	treated	for	decompensated	cirrhosis	and	
HCC	according	to	the	standard	of	care.
2.3 | Monitoring
Patients	 receiving	 therapy	 were	 reviewed	 at	 treatment	 weeks	 2,	 4,	
8,	12,	16,	20,	24,	36	and	48	and	at	post-	treatment	weeks	4	and	12.	
Clinical	status,	including	grade	of	ascites	and	hepatic	encephalopathy	
(HE),	and	laboratory	parameters,	measured	by	the	local	accredited	lab-
oratories,	were	recorded	on	eCRF	(Ibis	Informatica,	Milan,	Italy).	HCV-	
RNA	assessment	was	performed	either	by	Roche	High-	Pure-	System/
COBAS(®)	TaqMan(®)	v2.0	assay	(LLOQ	15	IU/mL;	Roche	Diagnostics,	
Indianapolis,	IN,	USA)	or	by	Abbott	real	time	assay	(LLOQ	12	IU/mL;	
Abbott	Molecular	 Inc.,	Des	 Plaines,	 IL,	USA).	MELD	 and	Child-	Pugh	
scores	were	calculated	using	site-	derived	laboratory	and	clinical	param-
eters.	Estimated	glomerular	filtration	rate	(eGFR)	was	using	the	Chronic	
Kidney	Disease	Epidemiology	Collaboration	(CKD-	EPI)	equation.11
2.4 | Statistical analysis
Data	were	expressed	as	absolute	number	and	percentages	for	discrete	
variables	and	as	median	and	minimum/maximum	values	for	quantita-
tive	 variables.	 For	 continuous	 variables	 normality	 of	 distribution	 and	
homogeneity	of	variances	were	assessed	by	the	Kolmogorov–Smirnov	
and	Levene	 test,	 respectively,	 afterward	differences	between	groups	
were	evaluated	by	the	Unpaired	Student’s	t-	test	or	Mann–Whitney	U 
test	as	appropriate.	Spearman’s	rank	correlation	method	was	used	to	
test	the	relationship	between	continuous	data.	Grouping	variables	were	
analysed	by	means	of	the	Chi-	square	test	or	Fisher	exact	test.	Change	
in	MELD	and	Child-	Pugh	scores	over	treatment	weeks	was	evaluated	
by	a	paired	data	Wilcoxon	rank	test,	while	the	cumulative	probability	
of	clinical	scores	 improvement	through	the	treatment	weeks	was	es-
timated	by	the	Kaplan–Meier	method	followed	by	the	Log	Rank	test	
to	evaluate	 the	difference	between	groups.	All	 tests	were	two-	tailed	
and P	values	less	than	.05	were	considered	statistically	significant.	The	
statistical	analysis	was	performed	by	the	Statistical	Package	for	Social	
Sciences	 (spss)	 software	 version	 23	 (IBM	 corporation,	 Armonk,	 NY,	
USA).
3  | RESULTS
3.1 | Patients
Between	June	2014	and	December	2014,	243	patients	listed	for	LT	
in	 the	 Italian	 transplant	centres	 received	SOF/R	within	 the	national	
ITACOPS	program.	As	shown	 in	Figure	1,	of	 these	243	patients,	19	
(7.8%)	were	excluded	by	the	present	analysis	because	the	data	were	
not	provided	by	 the	 investigators	or	were	 insufficient	 to	assess	 the	
virological	and	clinical	outcomes.
Thus,	the	study	population	consisted	of	224	patients.	The	demo-
graphic	and	baseline	clinical	and	laboratory	characteristics	of	these	pa-
tients	are	reported	in	Table	1.	Median	age	was	56	years	and	74%	were	
male.	Genotype	1b	(44%)	was	the	most	frequent	genotype	followed	
by	 genotype	3	 and	1a.	HCC	was	 present	 in	 107	patients	 (48%).	As	
expected,	MELD	and	Child-	Pugh	score	were	lower	in	HCC	than	non-	
HCC	patients	(MELD:	10.5	[6-	23]	vs	15	[9-	24],	Child-	Pugh:	7		[5-	12]	
vs	8	[7-	12]	respectively).	Nine	patients	were	also	positive	for	the	anti-
body	against	HIV	and	four	patients	for	serum	HBsAg.
Of	the	224	patients,	26	patients	discontinued	prematurely	treat-
ment	(24	[3-	47]	weeks):	11	patients	died	for	complications	of	cirrhosis,	
three	 patients	 presented	 a	 treatment	 virological	 failure	 (two	 non-	
responders	and	one	virological	breakthrough),	six	patients	were	forced	
to	interrupt	therapy	due	to	severe	anaemia,	four	patients	decided	to	
interrupt	the	study,	and	two	patients	were	excluded	for	medical	deci-
sion	(progression	of	HCC	in	one	case	and	scarce	adherence	to	treat-
ment	in	the	other).
As	a	result,	198	patients	reached	the	end	of	treatment:	100	were	
transplanted	during	treatment	and	98	completed	the	course	of	ther-
apy	without	LT.
3.2 | Treatments
According	to	the	study	protocol,	SOF	was	given	in	association	with	R	
in	all	patients.	However,	the	starting	dose	of	R	was	lower	than	the	sug-
gested	weight-	based	dosage	 (1000-	1200	mg	daily)	 in	119	 (59%)	pa-
tients.	Thus,	the	median	initial	R	daily	dose	was	800	mg		(200-	1200	mg).	
Genotype	1	patients	were	treated	for	48	weeks,	while	genotype	2	pa-
tients	 for	24	weeks.	Seven	of	50	patients	with	genotype	3	 received	
SOF/R	for	24	weeks	according	to	investigator’s	choice.	Furthermore,	
22	 (9.8%)	 patients	 were	 also	 treated	 with	 a	 second	 DAA	 obtained	
through	a	company-	driven	compassionate	program	(18	patients	with	
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daclatasvir	[12	genotype	1,	4	genotype	3,	and	2	genotype	4]	and	four	
patients	with	simeprevir	[all	genotype	1])	and	their	length	of	treatment	
was	12	or	24	weeks.	Clinical	and	virological	outcomes	of	the	22	pa-
tients	receiving	a	second	DAA	are	reported	in	Fig.	S1.
3.3 | Clinical and virological outcomes
Virological	clearance,	as	defined	by	HCV-	RNA	not	detected,	occurred	
in	204	(91%)	patients	during	treatment.	The	median	time	to	clearance	
was	4	weeks	(min/max	1-	28).	Seventeen	(7.6%)	patients	received	LT	
(median	treatment	duration	4	[0-	13]	weeks)	or	discontinued	prema-
turely	 the	 drugs	 (median	 treatment	 duration	 6	 [3-	17]	weeks)	when	
they	were	still	viraemic;	two	patients	failed	to	clear	HCV-	RNA	and	one	
patient	showed	a	virological	breakthrough.
Of	the	98	patients	who	completed	the	planned	course	of	therapy	
without	LT,	in	agreement	to	what	already	reported,12	73%	of	the	pa-
tients	showed	a	SVR12	according	to	the	Intention-	To-	Treat	(ITT)	anal-
ysis,	while	 the	 remaining	 relapsed,	 except	one	patient	who	died	 for	
bacterial	infection	after	having	obtained	the	SVR4	(Figure	1).
Although	not	included	in	the	initial	study	protocol,	many	investiga-
tors	decided	to	continue	treatment	after	LT	(bridging	therapy),	consid-
ering	 the	available	data	of	a	high	probability	of	viral	 recurrence	 if	 the	
period	of	HCV-	RNA	clearance	before	LT	was	shorter	 than	4	weeks.10 
Bridging	therapy	was	in	fact	performed	in	37	of	the	100	patients	who	
received	LT.	Of	 these	37	patients,	19	were	still	HCV-	RNA	positive	at	
LT	and	15	patients	were	negative	for	 less	than	4	weeks:	two	patients	
died	after	LT	due	to	multiple	organ	failure	and	two	patients	presented	a	
virological	relapse.	In	the	remaining	3	cases	of	bridging	therapy	with	un-
detectable	HCV-	RNA	for	more	than	4	weeks,	two	received	a	graft	from	
a	HCV	positive	donor,	and	in	the	third	the	period	of	clearance	before	
LT	was	only	5	weeks:	all	these	three	patients	reached	an	SVR12.	Taken	
together,	SVR12	was	88%	(33/37)	according	to	the	ITT	analysis	and	94%	
(33/35)	excluding	the	two	deaths	(Figure	1).	The	median	DAA	treatment	
duration	was	6	(0-	37)	weeks	before	LT	and	17	(4-	27)	weeks	after	LT.
Fifteen	patients	negative	for	less	than	4	weeks	at	LT	stopped	ther-
apy:	three	patients	died	for	early	LT	complications	and	four	patients	
presented	a	virological	relapse.	Thus,	SVR12	was	53%	according	to	ITT	
analysis	(8/15)	and	67%	(8/12)	excluding	the	three	deaths	(Figure	1).
Finally,	 48	 patients	 stopped	 therapy	 at	 LT	 being	 the	 HCV-	RNA	
undetectable	for	more	than	4	weeks	with	an	SVR12	of	88%	(42/48).
Overall,	 in	 transplanted	 patients	 SVR12	 was	 achieved	 in	 83%	
(83/100)	of	the	patients,	by	ITT	analysis,	and	87%	(83/95)	excluding	
the	five	deaths.
The	virological	outcome	in	the	different	subgroups	according	the	
HCV	genotypes	is	reported	in	Fig.	S2.
3.4 | Effect of treatment on liver function
To	determine	the	effect	of	treatment	on	liver	function,	we	first	ana-
lysed	the	changes	in	MELD	(n	=	126)	and	Child-	Pugh	(n	=	124)	scores	
in	the	patients	who	were	not	transplanted	in	the	initial	24	weeks	of	the	
study	with	data	available	at	baseline	and	after	24	weeks	of	therapy.	
F IGURE  1 Clinical	and	virological	
outcome	of	waitlisted	patients	enrolled	in	
the	compassionate	national	program	for	the	
use	of	sofosbuvir.	LT,	liver	transplantation;	
SVR,	sustained	virological	response
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MELD	 decreased	 in	 45%	 of	 cases,	 increased	 in	 33%	 and	 remained	
stable	in	22%	(P	=	.292),	while	Child-	Pugh	decreased	in	53%	of	cases,	
	increased	 in	 19%	 and	 remained	 stable	 in	 28%	 (P	=	.001).	 Notably,	
when	patients	were	divided	according	to	the	severity	of	liver	disease,	a	
significant	improvement	of	the	scores	was	observed	only	in	those	with	
basal	MELD	≥15	(n	=	50;	P	=	.019)	or	Child-	Pugh	≥8	(n	=	67;	P	=	.001).	
In	 these	 latter	 subgroups,	 the	median	drop	of	MELD	 score	was	3.5	
points	with	a	wide	range	comprised	between	1	and	15,	while	the	me-
dian	Child-	Pugh	reduction	was	2	points	with	a	range	between	1	and	4.
Due	to	this	high	variability,	we	then	decided	to	assess	the	cumula-
tive	probability	of	having	a	decrease	of	at	least	3	points	in	the	MELD	
score	and	at	least	2	points	in	the	Child-	Pugh	score,	an	extent	that	may	
reflect	a	relevant	clinical	improvement	(Figure	2).	In	patients	with	less	
severe	disease	identified	by	MELD	<15	or	Child-	Pugh	<B8,	the	prob-
ability	of	having	such	a	decrease	 in	the	MELD	score	was	about	20%	
and	30%	after	24	and	48	weeks,	respectively,	while	the	probability	in	
the	Child-	Pugh	score	was	about	20%	and	35%	after	24	and	48	weeks	
respectively.	When	we	consider	the	subgroup	with	a	more	severe	liver	
disease,	 the	 probability	 was	 significantly	 higher	 for	 both	 prognostic	
scores,	being	around	35%	after	24	weeks	and	65%	after	48	weeks	for	
MELD	and	50%	after	24	weeks	and	60%	after	48	weeks	for	Child-	Pugh.
3.5 | Effect of treatment on potential 
inactivation and delisting
To	assess	whether	the	clinical	 improvement	may	lead	to	inactivation	
and	delisting	of	patients,	we	analyzed	the	clinical	outcome	of	the	90	
patients	with	basal	MELD	≥15	and/or	Child-	Pugh	≥8	without	HCC,	
TABLE  1 Anthropometric,	virological,	clinical	and	biochemical	
parameters	of	224	patients	at	study	inclusion.	Data	are	expressed	as	
median	(min-	max	value)	or	frequencies	[n	(%)]
Median (min- max)/n (%)
Anthropometric
Age	(y) 56	(25-	70)
Weight	(kg) 73	(35-	115)
Gender	(male) 165	(74)
Virological
Genotype	(1/2/3/4) 134/17/50/23	(61/7/22/10)
HCV-	RNA	[log(IU/mL)] 5.5	(0.9-	7.3)
Previous	treatment 123	(55)
HBsAg	positive 4	(1.7)
HIV	positive 9	(4.0)
Clinical
HCC 107	(48)
Ascites	(none/mild/severe) 73/125/27	(33/55/12)
HE	(none/mild/severe) 122/94/8	(54/42/4)
Child-	Pugh	class	(A/B/C)	(all	pts) 46/135/43	(21/60/19)
Child-	Pugh	score	(all	pts) 8	(5-	12)
Child-	Pugh	score	(pts	with	HCC) 7	(5-	12)
Child-	Pugh	score	(pts	without	
HCC)
8	(7-	12)
MELD	(all	pts) 13	(6-	24)
MELD	(pts	with	HCC) 10.5	(6-	23)
MELD	(pts	without	HCC) 15	(9-	24)
Biochemical
Bilirubin	(mg/dL) 5.5	(0.4-	19.7)
INR 1.3	(1-	2.3)
Albumin	(g/dL) 3.4	(1.5-	5.2)
Creatinine	(mg/dL) 0.8	(0.5-	1.5)
eGFR	(ml/min/1.73	m2) 101.2	(31.6-	128.4)
AST	(IU/L) 75	(17-	544)
ALT	(IU/L) 59	(9-	522)
Hb	(g/dL) 11.8	(7.7-	16.7)
Platelets	(109/L) 66	(12-	285)
F IGURE  2 Cumulative	probability	of	presenting	a	reduction	in	at	
least	3	points	in	the	MELD	score	of	patients	with	a	basal	score	≥15	
or	<15	(Panel	A)	and	of	at	least	2	points	in	the	Child-	Pugh	score	of	
patients	with	a	basal	score	≥B8	or	<B8	(Panel	B)
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thus	with	a	clear	indication	to	OLT	based	on	clinical	liver	decompen-
sation	(Figure	3A).	We	also	decided	to	consider	patients	as	potential	
candidates	 for	 inactivation	 and	 delisting	when	 they	 reached	 a	 con-
dition	defined	by	Child-	Pugh	class	A	 invariably	 associated	 to	MELD	
score	<15.
During	 the	 entire	 period	 of	 observation	 of	 60	weeks,	 36	 pa-
tients	 were	 transplanted	 and	 2	 died	 for	 complications	 of	 liver	
disease.	We	 also	 excluded	 five	 patients	 with	 a	 follow-	up	 shorter	
than	 24	weeks.	Of	 the	 remaining	 47	 patients	 (median	 follow-	up:	
48	weeks	 [min/max:	24-	60]),	 15	became	Child-	Pugh	class	A	asso-
ciated	 to	 a	MELD	 score	<15	at	 the	 last	 available	 follow-	up.	Thus,	
17.4%	 of	 patients	 presented	 clinical	 scores	 suitable	 for	 inactiva-
tion	 and	 then	 delisting	 (Figure	3B).	 Figure	3C	 shows	 changes	 of	
the	 MELD	 and	 Child-	Pugh	 scores	 observed	 in	 these	 15	 patients	
from	baseline	to	the	last	visit	available	(median	follow-	up:	56	weeks	
[min/max:	 24-	60]).	 Interestingly,	 the	 pre-	treatment	 highest	MELD	
was	22	and	Child-	Pugh	was	C10.
To	identify	predictors	of	inactivation,	we	compared	at	the	univar-
iate	 analysis	 both	 static	 factors	 (demographic,	 virological	 and	 clini-
cal	characteristics	at	baseline)	and	dynamic	factors	 (improvement	of	
MELD	and	Child-	Pugh	scores	and	of	their	individual	components	after	
4	weeks	of	therapy)	between	the	15	patients	who	became	Child-	Pugh	
class	A	with	MELD	<15	and	the	71	patients	who	did	not.	Among	the	
static	 factors,	 predictors	 of	 inactivation	were	 baseline	 lower	 Child-	
Pugh	 score	 and	 absence	of	HE,	while	 the	Delta	MELD	 score,	Delta	
albumin,	Delta	 bilirubin	 and	Delta	 INR	were	 associated	 to	potential	
inactivation	among	the	dynamic	parameters	(Table	S1).	Finally,	the	cu-
mulative	probability	to	become	candidates	for	 inactivation	 increases	
progressively	with	the	extent	of	MELD	score	improvement,	reaching	a	
level	of	about	65%	in	those	patients	who	improved	their	MELD	of	at	
least	2	points	after	4	weeks	of	therapy.	Furthermore,	a	condition	suit-
able	for	inactivation	is	reached	faster	in	patients	presenting	a	greater	
week	0-	4	Delta	MELD	(Fig.	S3).
3.6 | Tolerability of treatment
No	serious	drug	reactions	were	associated	to	SOF	treatment.	As	ex-
pected,	the	major	side-	effect	related	to	R	was	anaemia,	which	required	
dose	reduction	in	about	30%	of	cases,	erythropoietin	administration	in	
18%	of	cases,	and	blood	transfusions	in	11%	of	cases.	Antiviral	treat-
ment	was	discontinued	due	to	anaemia	only	in	six	patients.
A	significant	correlation	was	found	between	the	starting	dose	of	R	
and	the	eGFR	(Spearman	rho	coefficient	0.199,	P	=	.005).	Finally,	side-	
effects	related	to	R	were	more	frequently	observed	in	patients	with	a	
lower	basal	eGFR	although	the	difference	did	not	reach	the	statistical	
significance	(Fig.	S4).
F IGURE  3 Clinical	improvement	suitable	for	inactivation	and	
delisting	in	patients	on	liver	transplant	waiting-	list	without	HCC	
and	MELD	≥15	and/or	Child-	Pugh	≥	B8.	Panel	A,	distribution	of	
MELD	and	Child-	Pugh	score	before	treatment	initiation.	Panel	B,	
distribution	of	MELD	and	Child-	Pugh	at	the	last	available	visit	in	the	
47	patients	with	at	least	24	wk	of	follow-	up.	Panel	C,	changes	from	
baseline	to	the	last	visit	available	in	MELD	and	Child-	Pugh	scores	
of	the	15	patients	reaching	a	condition	suitable	for	inactivation	
and	delisting	(Child-	Pugh	class	A	with	MELD	score	<15).	HCC,	
hepatocellular	carcinoma;	LT,	liver	transplantation
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4  | DISCUSSION
We	 have	 here	 reported	 a	 multicentre,	 real-	life	 experience	 in	 224	
pre-	transplant	patients	with	or	without	HCC	who	have	received	pri-
ority	access	to	SOF	through	a	compassionate	use	national	program.	
Although	SOF/R	 is	now	considered	a	sub-	optimal	therapy	since	the	
new	DAA	combinations	achieve	much	higher	SVR	rates	and	require	
a	shorter	course	of	 therapy,1-4	our	proof-	of-	concept	study	provides	
some	new	highlights	on	 the	effects	of	viral	eradication	 in	LT	candi-
dates,	a	setting	where	data	are	still	limited.
The	first	piece	of	information	regards	the	impact	of	pre-	LT	treat-
ment	on	the	prevention	of	the	almost	universal	graft	reinfection.	Curry	
et	al10	 showed	 that	 antiviral	 treatment	 can	effectively	prevent	HCV	
recurrence	 only	 if	 the	 patients	 have	 undetectable	 HCV-	RNA	 for	 at	
least	30	days	before	LT.	However,	these	data	were	confined	to	Child	
A	 patients	with	 HCC.	 Two	 novel	 data	 emerge	 from	 the	 analysis	 of	
our	patients	who	were	 transplanted	and	achieved	an	overall	SVR12	
in	87%	of	cases:	 first,	antiviral	 treatment	can	avoid	graft	 reinfection	
also	in	Child	B	and	C	patients;	second,	very	high	SVR	can	be	obtained	
even	in	patients	negative	at	transplantation	for	 less	than	30	days	or	
still	positive	while	on	treatment	by	continuing	antiviral	therapy	after	
LT	 (bridging	 therapy).	 Taking	 into	 consideration	 the	 landmark	 study	
by	Curry	et	al10	and	the	report	of	an	individual	case	of	bridging	ther-
apy	available	at	that	time,13	most	of	our	clinicians	decided	to	perform	
bridging	therapy	in	the	majority	of	patients	who	were	still	positive	or	
HCV-	RNA	negative	for	less	than	30	days	at	LT,	achieving	an	SVR12	of	
94%	in	those	who	survived	after	surgery,	which	was	much	higher	than	
the	67%	observed	 in	 those	who	 stopped	 therapy	at	 the	 time	of	LT.	
A	detailed	description	of	the	clinical	course	of	our	patients	receiving	
bridging	therapy	has	been	recently	published.14
It	can	be	argued	that	in	patients	with	a	very	short	expected	wait-
ing	time	antiviral	therapy	can	be	differed	and	started	after	hepati-
tis	recurrence	since	the	SVR	rates	in	transplant	patients	are	higher	
than	 those	observed	 in	decompensated	 cirrhosis.1,2,15	However,	 it	
can	also	occur	that	patients	in	stable	conditions,	for	whom	the	full	
course	of	 therapy	 is	 expected	 to	 be	 completed,	 develop	 an	 acute	
complication	that	leads	to	a	rapid	clinical	deterioration	and	to	high	
priority	for	organ	allocation.	For	the	few	patients	on	antiviral	treat-
ment	who	are	still	viraemic	at	the	time	of	LT	or	who	did	not	achieve	
viral	 clearance	 for	 at	 least	 30	days,	 the	 recommendations	 of	 the	
European	Liver	and	Intestine	Transplant	Association	(ELITA),	based	
on	 the	 expert	 opinion,	 state	 that	 bridging	 therapy	 can	 be	 consid-
ered.16	Our	 study	provides	 real	 data	 in	 favour	of	 the	efficacy	 and	
safety	of	this	approach.
The	second	contribution	of	the	present	study	is	related	to	the	im-
pact	of	antiviral	treatment	on	liver	function	and	inactivation/delisting	
for	 waitlisted	 patients.	 Consistently	 with	 previous	 studies,1-4	 40%-	
50%	of	our	patients	presented,	after	24	weeks	of	therapy,	an	improve-
ment	of	their	MELD	and	Child-	Pugh	scores,	which	was	clearly	more	
evident	in	patients	with	a	more	severe	disease,	as	defined	by	MELD	
≥15	or	Child-	Pugh	≥B8.
Based	on	the	median	decrease	of	MELD	and	Child-	Pugh	scores	in	
this	latter	subgroup	of	patients,	we	have	also	calculated	the	probability	
of	having	an	improvement	of	at	least	3	points	of	MELD	and	2	points	
of	Child-	Pugh	during	the	entire	length	of	the	study.	Three	interesting	
results	 emerged	 from	 this	 analysis:	 first,	 the	 probability	was	 signifi-
cantly	higher	in	patients	with	a	more	advanced	disease;	second,	about	
half	of	patients	present	a	decrease	of	their	scores	of	such	an	extent	
which	may	be	of	 clinical	 relevance;	 and	 third,	 the	 improvement	 be-
comes	manifest	 already	 few	weeks	 after	 the	 initiation	of	 therapy	 in	
some	patients	and	occurs	within	24	weeks	in	most	of	them.
If	obtaining	a	clinical	improvement	or	even	blocking	the	progres-
sion	of	 the	disease	obviously	 represents	a	goal	of	 therapy	 in	all	pa-
tients	with	decompensated	cirrhosis	who	do	not	have	 indication	for	
LT,	 this	may	be	not	the	case	of	waitlisted	patients	as	the	MELD	 im-
provement	 can	 also	 reduce	 the	priority	 for	 LT	 in	 the	 centres	where	
organ	 allocation	 is	 based	 on	 disease	 severity	 (the	 so	 called	 “MELD	
purgatory”).	Thus,	 in	 this	 specific	 setting,	 a	 critical	 issue	 appears	 to	
determine	which	patients	 can	be	 inactivated	and	 then	delisted	as	 a	
result	of	viral	eradication.
Belli	 et	al8	 have	 shown	 that,	 in	 patients	with	HCV-	related	 cir-
rhosis	treated	with	DAAs,	27.6%	of	patients	have	been	effectively	
inactivated	and	10.3%	delisted	after	48	weeks,	even	if	these	results	
could	have	been	influenced	by	the	behaviour	and	policies	of	the	dif-
ferent	transplant	centres.	In	our	study,	we	do	not	have	information	
regarding	the	real	 inactivation	and	de-	listing	rate.	Thus,	to	 investi-
gate	the	effect	of	antiviral	treatment	on	these	critical	outcomes,	we	
first	identified	the	cohort	of	90	patients	for	whom	the	indication	for	
LT	was	 clearly	 justified	by	 the	 severity	 of	 the	disease	 (MELD	≥15	
and/or	Child-	Pugh	≥B8)	and	not	by	the	presence	of	HCC	or	by	other	
MELD	exceptions.	Then,	we	arbitrary	defined	a	condition	that	can	
be	reasonably	associated	to	inactivation	and	de-	listing	in	the	clinical	
practice:	Child-	Pugh	A	 invariably	associated	to	MELD	<15.	During	
follow-	up,	15	(17.6%)	patients	reached	this	condition	after	a	median	
length	of	treatment	equal	to	36	weeks,	which	was	consistent	with	
the	rates	of	inactivation	reported	by	Belli	et	al	(15.5%	at	24	weeks	
and	27.6%	at	48	weeks).8	It	is	important	to	note	that	none	of	our	15	
patients	had	a	basal	MELD	>22	and	a	Child-	Pugh	>C10.
Beside	 a	 baseline	 lower	 Child-	Pugh	 score	 and	 less	 HE	 preva-
lence,	patients	who	reached	the	condition	suitable	for	 inactivation	
had	 a	 significantly	 greater	 improvement	 of	 MELD	 scores	 and	 its	
components	as	well	as	of	serum	albumin	after	4	weeks	of	therapy	
compared	 to	 those	who	 did	 not.	As	 a	 result,	 the	 delta	MELD	be-
tween	0	and	4	weeks	was	found	able	to	stratify	patients	for	achiev-
ing	 a	 condition	 of	 potential	 inactivation	 with	 a	 probability	 after	
48	weeks	 of	 about	 20%	 if	MELD	 after	 4	weeks	 increased,	 50%	 if	
MELD	remained	stable	or	decreased	1	point,	and	65%	if	decreased	
of	 at	 least	 2	points.	Taken	 together,	 these	data	 suggest	 that	 non-	
HCC	patients	 even	with	 a	 quite	 advance	 liver	 disease	 still	 carry	 a	
considerable	possibility	 to	avoid	LT	for	clinical	 improvement	and	a	
decrease	of	the	MELD	score	within	4	weeks	of	treatment	may	help	
to	identify	patients	with	higher	chances.
In	conclusion,	 the	 Italian	SOF	compassionate	use	program	showed	
that	a	pretransplant	therapeutic	approach	can	prevent	graft	reinfection	
in	almost	90%	of	 the	 recipients	provided	 that	bridging	 therapy	 is	per-
formed	in	those	patients	still	viraemic	or	negative	for	less	than	4	weeks	
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at	 transplantation.	 Furthermore,	 viral	 eradication	 is	 associated	 to	 an	 
improvement	of	liver	function	in	more	than	half	of	the	cases,	which	can	
reach	a	 condition	of	 inactivation	and	 then	de-	listing	 in	almost	20%	of	
non-	HCC	 patients	 including	 some	with	 a	 severely	 compromised	 liver	
function.
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